You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

429 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Mar 2026
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Archived
ID: FA3
Aug 2016
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Mar 2026
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Neoadjuvant, Adjuvant
Updated
Apr 2026
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Neoadjuvant, Adjuvant
New
Apr 2026

Pages